SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company focused on developing potentially best-in-class, oral
therapies for the treatment of chronic inflammatory and autoimmune
diseases, today announced management's participation in the
following investor and scientific conferences in October:
- October 2-4: 2019
Cantor Global Healthcare Conference: Daniel Vitt, Ph.D., Chief Executive Officer and
President of Immunic, will present a company overview at the 2019
Cantor Global Healthcare Conference in New York on Friday,
October 4, at 12:35 pm EDT. A
live audio webcast of the presentation will be available on the
"Events and Presentations" section of Immunic's website at:
ir.immunic-therapeutics.com. An archived replay will be available
on the company's website for a period of 90 days after the
conference.
- October 19-23: United European
Gastroenterology Week (UEGW): Hella
Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will
present a poster highlighting selected data regarding the company's
lead oral compound, IMU-838, currently in phase 2 clinical
development for the treatment of ulcerative colitis,
relapsing-remitting multiple sclerosis and primary sclerosing
cholangitis, at the UEGW in Barcelona,
Spain.
-
- Abstract Number: P1021
- Title: Preclinical Investigations of IMU-838, an Orally
Available Small Molecule Inhibitor of Dihydroorotate Dehydrogenase
for the Treatment of Inflammatory Bowel Disease
- Poster Session: IBD II
- Session Date: Tuesday, October
22
- Presenting Time: 9:00 am –
5:00 pm CEST
- Session Location: Poster exhibition – Hall 7
In conjunction with its participation at UEGW, Immunic will also
host a meeting, featuring key international experts, to discuss the
potential of the company's IMU-838 and IMU-856 programs. This
renowned group will help to guide Immunic in the selection of
indications with highest medical need, trial design and endpoints,
and best service providers and trial locations.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
clinical-stage biopharmaceutical company developing a pipeline of
selective oral immunology therapies aimed at treating chronic
inflammatory and autoimmune diseases, including relapsing-remitting
multiple sclerosis, ulcerative colitis, Crohn's disease, and
psoriasis. The company is developing three small molecule products:
IMU-838 is a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal barrier function.
Immunic's lead development program, IMU-838, is in phase 2 clinical
development for relapsing-remitting multiple sclerosis and
ulcerative colitis, with an additional phase 2 trial planned in
Crohn's disease. An investigator-sponsored proof-of-concept
clinical trial for IMU-838 in primary sclerosing cholangitis is
ongoing at the Mayo Clinic. For further information, please visit:
www.immunic-therapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's participation in investor and scientific conferences.
Immunic may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in the
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, risks
and uncertainties associated with the ability to project future
cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient
resources to meet business objectives and operational requirements,
the fact that the results of earlier studies and trials may not be
predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section
captioned "Item 1A. Risk Factors," in the company's Current Report
on Form 8-K filed on July 17, 2019,
and in the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov or ir.immunic-therapeutics.com/sec-filings and on
request from Immunic. Any forward-looking statement made in this
release speaks only as of the date of this release. Immunic
disclaims any intent or obligation to update these forward-looking
statements to reflect events or circumstances that exist after the
date on which they were made. Immunic expressly disclaims all
liability in respect to actions taken or not taken based on any or
all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de
Or
Rx Communications Group
Melody Carey
+1-917-322-2571
immunic@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-october-300927529.html
SOURCE Immunic, Inc.